Utilization Patterns of Lipid-lowering Therapies in Patients With Atherosclerotic Cardiovascular Disease or Diabetes: A Population-based Study in South Korea

被引:3
|
作者
Kim, Siin [1 ]
Kim, Hyungtae [1 ]
Kim, Eunju [1 ]
Han, Sola [1 ]
Rane, Pratik P. [2 ]
Fox, Kathleen M. [3 ]
Zhao, Zhongyun [2 ]
Qian, Yi [2 ]
Suh, Hae Sun [1 ]
机构
[1] Pusan Natl Univ, Coll Pharm, Busan, South Korea
[2] Amgen Inc, Thousand Oaks, CA 91320 USA
[3] Strateg Healthcare Solut LLC, Aiken, SC USA
关键词
adherence; atherosclerotic cardio-vascular disease; diabetes; statin; statin intolerance; treatment pattern; LONG-TERM PERSISTENCE; STATIN THERAPY; ADHERENCE; RISK; NONADHERENCE; TERMINOLOGY; ASSOCIATION; CHOLESTEROL; MANAGEMENT; OUTCOMES;
D O I
10.1016/j.clinthera.2018.04.007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose: We aimed to study the utilization patterns of lipid-lowering treatment (LLT), including treatment modification, adherence, and possible statin intolerance , in patients with atherosclerotic cardiovascular disease (ASCVD) or diabetes using national claims data in South Korea. Methods: A retrospective cohort study was conducted using data from the Korean Health Insurance Review & Assessment Service claims database. Patients aged >= 18 years with > 1 outpatient pharmacy claim for a statin and/or ezetimibe dated January 1, 2012, to December 31, 2014, were identified and categorized into the following cohorts: patients with ASCVD, and patients with diabetes mellitus without ASCVD. LLT modification, adherence to index LLT, and possible statin intolerance were explored during the 12 months after the date of first prescription for a statin and/or ezetimibe. Findings: Among 1,399,872 patients who met the eligibility criteria, 807,547 (57.7%) were patients with ASCVD and 592,325 (42.3%) were patients with diabetes without ASCVD. About half of the patients had no modification in their index treatment (46.2% in the ASCVD cohort and 48.9% in the diabetes cohort), and the most common modification was permanent discontinuation (19.6% in the ASCVD cohort and 21.4% in the diabetes cohort). The mean medication possession ratios were 0.77 in the ASCVD cohort and 0.73 in the diabetes cohort and showed a decreasing trend during the 12-month follow-up period. Among patients who initiated a statin and/or ezetimibe, possible statin intolerance was observed in 53,921 patients (6.7%) in the ASCVD cohort and 42,172 patients (7.1%) in the diabetes cohort. (C) 2018 Elsevier HS Journals, Inc. All rights reserved.
引用
收藏
页码:940 / 951
页数:12
相关论文
共 50 条
  • [41] Use of Lipid-lowering Agents in Rheumatoid Arthritis: A Population-based Cohort Study
    Veetil, Bharath Manu Akkara
    Myasoedova, Elena
    Matteson, Eric L.
    Gabriel, Sherine E.
    Crowson, Cynthia S.
    JOURNAL OF RHEUMATOLOGY, 2013, 40 (07) : 1082 - 1088
  • [42] Lipid-Lowering Efficacy of Ezetimibe in Patients with Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analyses
    Shaya, Fadia Tohme
    Sing, Krystal
    Milam, Robert
    Husain, Fasahath
    del Aguila, Michael A.
    Patel, Miraj Y.
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2020, 20 (03) : 239 - 248
  • [43] Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease
    Chan, Joyce
    Rajalingam, Tharshan
    Fossella, Jonathon
    Zhou, Hui
    Eisenberg, Naomi
    Roche-Nagle, Graham
    ANNALS OF VASCULAR SURGERY, 2020, 69 : 197 - 205
  • [44] Lipid-Lowering Efficacy of Ezetimibe in Patients with Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analyses
    Fadia Tohme Shaya
    Krystal Sing
    Robert Milam
    Fasahath Husain
    Michael A. del Aguila
    Miraj Y. Patel
    American Journal of Cardiovascular Drugs, 2020, 20 : 239 - 248
  • [46] UTILIZATION PATTERNS OF LIPID-LOWERING MEDICATIONS IN HIGH RISK DIABETIC PATIENTS
    Vadhariya, A.
    Aparasu, R.
    VALUE IN HEALTH, 2016, 19 (03) : A3 - A3
  • [47] LIPID PROFILE AND LIPID-LOWERING THERAPY AMONG ACUTE MYOCARDIAL INFARCTION PATIENTS WITHOUT PREVIOUS ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
    Essa, Mohammed
    Lu, Yuan
    Huang, Haocheng
    Desai, Nihar R.
    Spatz, Erica Sarah
    Krumholz, Harlan M.
    Dajani, Abdel R.
    Mankbadi, Michael
    Kay, Bradley
    Faridi, Kamil
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 1987 - 1987
  • [48] Changes in lipid-lowering therapy following a cardiovascular event in patients with diabetes
    Okerson, T.
    Cohen, S. S.
    Killian, J. M.
    Weston, S. A.
    Monda, K. L.
    Chamberlain, A. M.
    DIABETOLOGIA, 2017, 60 : S537 - S538
  • [49] Are the lipid-lowering effects of incretin-based therapies relevant for cardiovascular benefit?
    Alnima, Teba
    Smits, Mark M.
    Hanssen, Nordin M. J.
    CURRENT OPINION IN LIPIDOLOGY, 2024, 35 (06) : 259 - 267
  • [50] Serum lipid profiles and uptake of lipid-lowering therapy in patients with premature atherosclerotic cardiovascular disease (ASCVD) in comparison to older patients with ASCVD
    Yao, W. X.
    Nawaz, S.
    Grover, J.
    Leung, A. N. W.
    Upadhyay, J.
    Theertham, A.
    Thondup, T.
    Samson, E.
    Bhat, A.
    Tan, T. C.
    EUROPEAN HEART JOURNAL, 2024, 45